Pfiz­er's mi­graine nasal spray from Bio­haven notch­es ap­proval

Pfiz­er’s nabbed its first ap­proval out of its Bio­haven ac­qui­si­tion with a nod for mi­graine spray Za­vzpret on Fri­day. The FDA ap­proval al­so marks a first in­tranasal de­liv­ery method among the new­er class of cal­ci­tonin gene-re­lat­ed pep­tide (CGRP) re­cep­tor an­tag­o­nists in mi­graine treat­ments.

Pfiz­er picked up za­veg­epant in its $11.6 bil­lion ac­qui­si­tion of Bio­haven, which al­so in­clud­ed Nurtec ODT and a pre­clin­i­cal port­fo­lio of CGRP as­sets, fi­nal­ized in Oc­to­ber. Bio­haven, or New Bio­haven, was spun out as a sep­a­rate com­pa­ny now de­vel­op­ing the re­main­ing non-CGRP as­sets, keep­ing the $BHVN tick­er and con­tin­u­ing to be led by CEO Vlad Coric.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER